DHR

Danaher is one of those compounders that has largely lost its luster in current market. However, Danaher shareholders cannot quite blame Mr. Market since 2Q’26 earnings didn’t provide much of an evidence of Danaher getting out of their growth slump that they have been under for multiple years.

Danaher had another somewhat uneventful quarter. Looking at Danaher’s numbers every quarter is a stark reminder just how anemic the growth has proved to be for a company that enjoys some supposedly secular tailwinds. Even if you adjust for their spin-off of Environmental & Applied solutions segment in

Following Sartorius 3Q’25 call, I mentioned in my update that I am actually a bit surprised that Danaher stock didn’t react more positively. Well, Danaher stock did pop ~8% after confirming bioprocessing’s continued growth and an initial 2026 guide that outlined HSD earnings growth even in a

While S&P 500 is at its all-time high, Danaher is still ~34% below its peak from late 2021. The company was beleaguered with pandemic hangover and destocking trends for much of 2022-24 period. While the worst seem to behind them, the business isn’t quite humming